Use of daratumumab in patients with amyloidosis
AUTOR(ES)
Anzai, Adriano; Utino, Armelin; Katayama, Haroldo; Spir, Ighor A. Z.; Lemos, Marcio A.; Anhesini, Mauricio; Tiezzi, Oswaldo S.; Spir, Patricia R. N.; Otani, Pericles; Bernardo, Wanderley M.
FONTE
Rev. Assoc. Med. Bras.
DATA DE PUBLICAÇÃO
2020-11
RESUMO
The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.
Documentos Relacionados
- Amyloidosis: the use of the Daratumumab
- Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis.
- Mortality from amyloidosis and renal diseases in patients with rheumatoid arthritis.
- Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review
- Class-specific rheumatoid factors, DR antigens, and amyloidosis in patients with rheumatoid arthritis.